Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

Get More Information

 

Request Services

 

Find Other Researchers

 

Research Toolkit

 

Clinical Research in Oklahoma

 

Citing the OSCTR

University of Oklahoma Health Sciences Receives Federal Funding to Improve Health Care Access Across the State

Submitted by alex on

Across large areas of Oklahoma and the nation, primary care clinics are a lifeline, providing care for people who otherwise would have to travel many miles to see a doctor. To increase access to vital health care, the National Institutes of Health announced an ambitious new initiative to integrate NIH-funded clinical trials into routine patient care in areas like rural Oklahoma and within Tribal nations.

OU Awarded $17 Million NIH Grant to Improve Cancer Outcomes Among Native Americans

Submitted by Anonymous (not verified) on

The National Institutes of Health has awarded the University of Oklahoma a five-year, $17.2 million grant to partner with tribal nations and communities to improve cancer outcomes. Research has shown that the American Indian and Alaska Native population in Oklahoma experiences a 36% higher incidence of cancer and a 73% higher death rate from cancer than faced by the U.S. general population.

OCTSI Director elected to National Academy of Medicine

Submitted by tvanwagoner on

Judith A. James, M.D., Ph.D., associate vice provost for clinical and translational science and professor of medicine at the University of Oklahoma Health Campus, has been elected to the National Academy of Medicine for her work in the field of autoimmunity and autoimmune disorders.

She is the first woman from an Oklahoma institution – and fifth overall Oklahoma-based scientist – to be selected for this prestigious honor, which is widely considered one of the highest honors in the fields of health and medicine.

Subscribe to News

Recent Publications

Endotoxin Markers Are Elevated in Adolescents With Obesity With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease

Pediatr Obes. 2026 Feb;21(2):e70093. doi: 10.1111/ijpo.70093.

ABSTRACT

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in paediatric patients. Adult and murine studies have suggested a role for endotoxin from gram-negative bacteria in the development of MASLD, but there is incomplete and conflicting evidence for its role in adolescents.

The "M" Word: Defining Malignancy in Surgical Residencies

J Surg Educ. 2025 Nov;82(11):103660. doi: 10.1016/j.jsurg.2025.103660. Epub 2025 Sep 25.

ABSTRACT

OBJECTIVE: We sought to define the term "malignancy" in the setting of medical students applying to general surgery residencies.

DESIGN: This was a retrospective qualitative analysis of Reddit.com's yearly General Surgery Match Application spreadsheets. Programs were marked as malignant (Y), nonmalignant (N), and Mixed (Y/N). A code book was developed and responses coded. Thematic and pattern analysis was performed.

A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis Rheumatol. 2025 Sep 16. doi: 10.1002/art.43391. Online ahead of print.

ABSTRACT

OBJECTIVE: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.

Media

Copyright © 2026 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies